CA2152912A1 - Cycloalkyl amine bis-aryl squalene synthase inhibitors - Google Patents

Cycloalkyl amine bis-aryl squalene synthase inhibitors

Info

Publication number
CA2152912A1
CA2152912A1 CA002152912A CA2152912A CA2152912A1 CA 2152912 A1 CA2152912 A1 CA 2152912A1 CA 002152912 A CA002152912 A CA 002152912A CA 2152912 A CA2152912 A CA 2152912A CA 2152912 A1 CA2152912 A1 CA 2152912A1
Authority
CA
Canada
Prior art keywords
hydrogen
hydroxy
alkyl
independently
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002152912A
Other languages
English (en)
French (fr)
Inventor
John W. Ullrich
Terence J. Kiesow
Kent W. Neuenschwander
Anthony C. Scotese
Keith S. Learn
William P. Dankulich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2152912A1 publication Critical patent/CA2152912A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/52—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CA002152912A 1992-12-29 1993-12-29 Cycloalkyl amine bis-aryl squalene synthase inhibitors Abandoned CA2152912A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/997,818 1992-12-29
US07/997,818 US5451596A (en) 1992-12-29 1992-12-29 Cycloalkyl amine bis-aryl squalene synthase inhibitors

Publications (1)

Publication Number Publication Date
CA2152912A1 true CA2152912A1 (en) 1994-07-07

Family

ID=25544432

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002152912A Abandoned CA2152912A1 (en) 1992-12-29 1993-12-29 Cycloalkyl amine bis-aryl squalene synthase inhibitors

Country Status (7)

Country Link
US (1) US5451596A (enExample)
EP (1) EP0676960B1 (enExample)
JP (1) JPH08505847A (enExample)
AU (1) AU6080694A (enExample)
CA (1) CA2152912A1 (enExample)
DE (1) DE69331954T2 (enExample)
WO (1) WO1994014435A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5665737B1 (en) * 1994-10-12 1999-02-16 Euro Celtique Sa Substituted benzoxazoles
CA2206287C (en) * 1994-12-13 2001-03-20 Mark Chasin Aryl thioxanthines
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
CA2206804C (en) * 1994-12-13 2002-03-19 Euro-Celtique, S.A. Trisubstituted thioxanthines
US5556990A (en) * 1994-12-16 1996-09-17 Rhone-Poulenc Rorer Pharmaceuticals Inc. Polyarylcarbamoylaza- and -carbamoylalkanedioic acids
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
AU6320998A (en) 1997-02-21 1998-09-09 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
MXPA00009593A (es) 1998-04-01 2004-03-10 Nortran Pharmaceuticals Inc Compuestos de eter aminociclohexilico y sus usos.
US6979685B1 (en) 1999-02-12 2005-12-27 Cardiome Pharma Corp. Cycloalkyl amine compounds and uses thereof
WO2000047547A2 (en) * 1999-02-12 2000-08-17 Nortran Pharmaceuticals Inc. Cycloalkyl amine compounds and uses thereof
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US7524879B2 (en) 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
EP1575575B1 (en) * 2002-11-08 2010-05-19 High Point Pharmaceuticals, LLC Safe chemical uncouplers for the treatment of obesity
NZ543921A (en) 2003-05-02 2008-11-28 Cardiome Pharma Corp Aminocyclohexyl ether compounds and uses thereof
US7345086B2 (en) 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US7674820B2 (en) 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
CA2561819A1 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
WO2005097087A2 (en) 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP5583325B2 (ja) 2004-11-08 2014-09-03 カーディオム ファーマ コーポレイション イオンチャネル調節化合物の投与レジメ
JP5507049B2 (ja) 2004-12-30 2014-05-28 アステックス、セラピューティックス、リミテッド 医薬品
WO2007027651A2 (en) * 2005-08-30 2007-03-08 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
JP5474354B2 (ja) 2005-12-30 2014-04-16 アステックス、セラピューティックス、リミテッド 医薬化合物
JP5523829B2 (ja) 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド 複合薬剤
CN102573473B (zh) 2009-06-09 2015-05-27 加利福尼亚资本权益有限责任公司 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物
CA2765044A1 (en) 2009-06-09 2010-12-16 California Capital Equity, Llc Benzyl substituted triazine derivatives and their therapeutical applications
CN102573480B (zh) 2009-06-09 2015-06-10 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
BR112017017032A2 (pt) 2015-02-11 2018-04-10 Basilea Pharmaceutica International AG derivados de mono e poliazanaftaleno substituídos e uso dos mesmos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447611A (en) * 1982-05-27 1984-05-08 American Home Products Corporation Benzo-fused and heterocyclic fused imidazole anti-ulcer agents
JO1410B1 (en) * 1984-11-03 1986-11-30 سميث كلاين اند فرينش لابوراتوريز ليمتد Compounds
CH667657A5 (de) * 1985-01-07 1988-10-31 Sandoz Ag Carbocyclische und heterocyclische carbonylmethylen- und methylpiperidine und -pyrrolidine.
US5053425A (en) * 1990-03-21 1991-10-01 Merck & Co., Inc. Novel anti-fungal compounds
US5055487A (en) * 1990-03-21 1991-10-08 Merck & Co., Inc. Novel anti-fungal compounds
US5091500A (en) * 1990-09-21 1992-02-25 The Dow Chemical Company Polybenzazole polymer containing perfluorocyclobutane rings
JP3095413B2 (ja) * 1990-12-28 2000-10-03 帝人株式会社 ベンゾオキサ縮合環化合物
WO1992015579A1 (en) * 1991-03-08 1992-09-17 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
US5135935A (en) * 1991-05-17 1992-08-04 Merck & Co., Inc. Squalene synthetase inhibitors
GB9122988D0 (en) * 1991-10-30 1991-12-18 Ici Plc Heterocyclic compounds

Also Published As

Publication number Publication date
US5451596A (en) 1995-09-19
WO1994014435A1 (en) 1994-07-07
JPH08505847A (ja) 1996-06-25
AU6080694A (en) 1994-07-19
EP0676960B1 (en) 2002-05-22
DE69331954D1 (de) 2002-06-27
EP0676960A4 (enExample) 1995-11-15
DE69331954T2 (de) 2002-11-28
EP0676960A1 (en) 1995-10-18

Similar Documents

Publication Publication Date Title
CA2152912A1 (en) Cycloalkyl amine bis-aryl squalene synthase inhibitors
US5596020A (en) Amino bi- and tri-carbocyclic alkane bis-aryl squalene synthase inhibitors
US5385912A (en) Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5556990A (en) Polyarylcarbamoylaza- and -carbamoylalkanedioic acids
RU2158733C2 (ru) Производные 2,8-дизамещенного хиназолинона или их соли, фармацевтическая композиция с воздействующей на уровень кгмп и камп активностью на их основе
EP0370901B1 (fr) Nouveaux dérivés du chromanne actifs sur le système nerveux central, leur procédé de préparation et les compositions pharmaceutiques en contenant
WO1992015579A1 (en) Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
FR2661676A1 (fr) Derives d'amino benzocycloalcanes, procedes de preparation et medicaments les contenant.
SK12297A3 (en) Benzoxazoles, pyridine derivatives, process for producing same pharmaceutical composition containing them, their use and intermediate product
JPH09505294A (ja) プロテアーゼ阻害剤および抗ウイルス剤としての５，６−ジヒドロピロン誘導体
KR20210082466A (ko) 샤페론-매개 자가포식작용 조절제로서 유용한 벤족사졸 및 관련된 화합물
JPH02134375A (ja) ３―オキシラニル安息香酸およびその誘導体
WO2017148417A1 (zh) 一种2,3-环氧丁二酰衍生物及其制备方法和用途
JP3068665B2 (ja) ピロ−ル誘導体
JP3140494B2 (ja) 置換されたフエニルアセチレン、これを含有する薬剤、この化合物及び薬剤を製造する方法
EP0406739A2 (en) Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same
US5455260A (en) Aliphatic amino bis-aryl squalene synthase inhibitors
Chan et al. Inhibitors of cholesterol biosynthesis. 1. 3, 5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and-heptanoates, a novel series of 3-hydroxy-3-methylglutarate-CoA reductase inhibitors
RU2153497C2 (ru) Производные пирона, фармацевтическая композиция с антивирусной и антибактериальной активностью на их основе и способ лечения вызванных ретровирусом инфекции или заболевания
CA1132983A (fr) Procedes de preparation de nouvelles piperazines monosubstituees
US20020082254A1 (en) Compounds for treating disorders where a decreased level of plasma FFA is desired
US5561143A (en) Aliphatic amino bis-aryl squalene synthase inhibitors
CA1209142A (fr) Procede d'obtention de nouvelles cyanoguanidines et des compositions pharmaceutiques en renfermant
EP0576349A1 (fr) Dérivés d'indolizines, procédé de préparation et utilisation pour la préparation de composés aminoalkoxybenzènesulfonyl-indolizines à activité pharmaceutique
EP0395526A1 (fr) Nouveaux dérivés benzothiazolinoniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued